Abstracts tagged "Adalimumab and inflammatory bowel disease (IBD)"

Abstract Number: 1931 • 2012 ACR/ARHP Annual Meeting
Influence of Trough Serum Drug Level and Immunogenicity On the Lack of Response to Adalimumab Therapy in Inflammatory Bowel Disease Patients
Shui Long Wang¹, Scott Hauenstein¹, Linda Ohrmund¹, Reshma Shringarpure², Douglas C. Wolf³, Isam A. Diab⁴, Jared Salbato¹, Rukmini Reddy¹, Kevin McCowen¹, Shawn Shah¹, Steven Lockton¹, Emil Chuang² and Sharat Singh¹, ¹Research and Development, Prometheus Laboratories, San Diego, CA, ²Clinical and Medical Affairs, Prometheus Laboratories, San Diego, CA, ³Atlanta Gastroenterology Associates, Atlanta, GA, ⁴Paramount Medical Research & Consulting, Middleburg Heights, OH
Background/Purpose: Anti-TNF-α therapy is effective for the treatment of inflammatory bowel disease (IBD). Nevertheless, over 30% of IBD patients fail to respond to anti-TNF-α therapy…